Bausch Health Companies Inc [NYSE: BHC] price plunged by -7.54 percent to reach at -$0.66. The one-year BHC stock forecast points to a potential upside of 22.95. The average equity rating for BHC stock is currently 2.86, trading closer to a bullish pattern in the
Bausch Health Companies Inc [NYSE: BHC] price surged by 0.95 percent to reach at $0.08. The one-year BHC stock forecast points to a potential upside of 16.13. The average equity rating for BHC stock is currently 2.86, trading closer to a bullish pattern in the
Bausch Health Companies Inc [NYSE: BHC] closed the trading session at $9.69. The company report on April 5, 2024 at 6:15 PM that Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals. Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) along with its gastroenterology business, Salix Pharmaceuticals, Inc., announced
Bausch Health Companies Inc [NYSE: BHC] stock went on an upward path that rose over 2.11% on Tuesday, amounting to a one-week price increase of more than 6.74%. The company report on February 22, 2024 at 7:00 AM that Bausch Health Announces Fourth-Quarter and Full-Year
Bausch Health Companies Inc [NYSE: BHC] jumped around 0.63 points on Thursday, while shares priced at $9.30 at the close of the session, up 7.27%. The company report on February 22, 2024 at 7:00 AM that Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results. Fourth-Quarter
Bausch Health Companies Inc [NYSE: BHC] closed the trading session at $7.85. The company report on January 30, 2024 at 8:00 AM that CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S. Bausch Health
© 2024, Powered by Smart TechOne
